文献速递乳腺癌放疗胸部肿瘤放疗泌尿生殖与妇科肿瘤放疗

乳腺癌、宫颈癌、肺癌、前列腺癌和直肠癌的放疗需求与利用:一项人群水平研究

Determining the need and utilization of radiotherapy in cancers of the breast, cervix, lung, prostate and rectum: A population level study.
PubMed 文献 · Radiother Oncol · 2016-12-21

结果显示观察到的放疗率低于两种估计,且短缺程度因癌种和估计方法而异。

要点

  • 乳腺癌RT-1y率为51.5%(95%CI 50.1-52.9)。
  • 直肠癌RT-1y率为39.3%(95%CI 36.5-42.1),短缺最高达30.3%。
  • 宫颈癌短缺最低为-0.3%(取决于CBB或EBEST)。

核心结论

  • 尽管实行集中化癌症诊疗和公共资助医疗体系,阿尔伯塔省仍存在放疗利用不足。
  • 解决短缺需注意模型选择对findings的影响。

研究设计与样本

  • 共纳入n=68,164例癌症病例,计算诊断后一年内放疗比例,并与文献中CBB和EBEST需求估计比较。

主要发现

  • RT-1y率(95%CI):乳腺癌51.5%(50.1-52.9),宫颈癌48.9%(43.8-54.0),肺癌37.1%(35.4-38.8),前列腺癌26.9%(25.1-28.7),直肠癌39.3%(36.5-42.1)。
  • 观察到的RT率低于CBB和EBEST估计,短缺范围从宫颈癌的-0.3%到直肠癌的30.3%。

关键数值与推荐

  • CBB和EBEST为文献中使用的需求估计方法,具体推荐条款未在摘要中报告。

临床怎么用

  • 临床可参考本研究中各癌种的RT-1y观察率及与需求估计的差距,识别放疗利用不足的癌种。

局限性

  • 需求估计依赖于文献中的CBB和EBEST模型,模型选择影响短缺评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Determining the appropriate rate of radiotherapy (RT) utilization is important for health care planning and resource allocation. The difference between the observed and the appropriate RT rate is influenced by the choice of a criterion based benchmarking (CBB) or evidence-based estimates (EBEST) measure. Our primary objective was to determine the utilization of radiotherapy for cancers of the breast (B), cervix (C), lung (L), prostate (P) and rectum (R) in Alberta (AB) Canada and to compare the observed RT rates to estimates of need derived from the criterion based benchmarking (CBB) and evidence-based estimates (EBEST). MATERIALS AND METHODS: All incident cases of B,C,L,P and R cancers diagnosed in AB during 2004-8 (prior to the decentralization of provincial RT capacity) were identified from the Alberta Cancer Registry. Patients receiving RT within one year (RT-1y) of diagnosis were identified and the proportion receiving RT-1y was then calculated. Factors associated with RT utilization were analysed by region. Estimates of the need for RT were derived from CBB and EBEST methods in the literature. RESULTS: A total of n=68,164 cancer cases were identified from the ACR. RT-1y rates (95% C.I.) were B: 51.5% (50.1-52.9), C: 48.9% (43.8-54.0), L: 37.1% (35.4-38.8), P: 26.9% (25.1-28.7) and R: 39.3% (36.5-42.1). Observed rates of RT in AB were lower than estimates derived using the CBB and EBEST estimates. Shortfalls varied across cancer sites according to whether a CBB or EBEST estimate was used ranging from a low of -0.3% in cancer of the cervix to a high of 30.3% in rectal cancer. CONCLUSIONS: RT shortfalls exist in the utilization of RT in AB, Canada despite centralized cancer care and a publically funded health care system. Decisions to address shortfalls need to be mindful of how model selection can impact on findings.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Shack L, Lu S, Weeks LA, et al. Determining the need and utilization of radiotherapy in cancers of the breast, cervix, lung, prostate and rectum: A population level study. Radiother Oncol. 2016. PMID: 28012795. doi:10.1016/j.radonc.2016.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。